Tactile Systems Technology, Inc. Q2 2026 Earnings Call Summary
Tactile Systems Technology reported Q2 2026 results: lymphedema revenue rose 12% YoY on Flexitouch adoption, while airway clearance revenue fell 7% as large DME partners paused orders amid elevated inventory. Gross margin increased 180 bps to 76.3%. Full-year 2026 revenue guidance was raised to $360m-$366m; MyoSleeve launch and LymphaTech FDA submission are ongoing.
How this was made
The 30-second read
Why it matters
Traders can update models using the revised FY 2026 revenue range, gross margin expansion, and the expected Q3 normalization path for airway-clearance ordering. The call also frames reimbursement progress for LymphaTech (FDA submission underway, Category III CPT pursuit) and administrative normalization for lymphedema orders.
Market read
The most tradable elements are the updated FY 2026 revenue guidance ($360M-$366M), the gross margin expansion to 76.3%, and the Q3 timing narrative around Medicare prior authorization and DME inventory rebalancing.
What to watch
Cash decline from MyoSleeve distribution rights and buybacks could constrain flexibility if adoption ramps slower than management expects, despite no material MyoSleeve revenue assumed in 2026 guidance.
Background
The article summarizes Tactile Systems Technology’s Q2 2026 earnings call, focusing on lymphedema and airway-clearance revenue drivers, Medicare prior authorization impacts, and pipeline/reimbursement milestones for LymphaTech and MyoSleeve.
Ticker impact
Tactile Systems updated full-year 2026 revenue guidance to $360M-$366M and flagged Q3 airway-clearance ordering headwinds tied to DME inventory normalization.
Moderate upside bias if investors focus on lymphedema growth and gross margin expansion, but near-term caution from airway-clearance ordering pause.
The article provides multiple decision-relevant datapoints: updated FY range, Q3 ordering normalization timeline, gross margin expansion to 76.3%, and cash decline drivers. However, it is a call summary rather than a fresh filing, limiting certainty on incremental new information versus already-known guidance.
Market effects
Highlights reimbursement and administrative friction risk in durable medical equipment and compression-device adoption, which can affect sentiment across medtech reimbursement-sensitive names.
None material indicated.
None material indicated.
Counterpoint
The Q3 sequential step-up may be largely mechanical from order shifting due to prior authorization timing, not a fundamental demand re-acceleration.
Key entities
- companyTactile Systems Technology, Inc.
Subject of the earnings call summary, providing updated 2026 guidance, segment performance drivers, and reimbursement and pipeline milestones.
- productLymphaTech
Diagnostic aid with FDA submission underway, expected approval in 2027, and pursuit of Category III CPT code for reimbursement pathway.
- productMyoSleeve
Non-pneumatic compression device leveraging existing VA infrastructure; MyoSleeve distribution rights drove upfront cash outflows, with 2026 guidance not assuming material revenue contribution.
- productAffloVest
Next-generation airway clearance system; management notes it does not command incremental reimbursement, acting mainly as a competitive differentiator.
